{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:56:57Z","timestamp":1760853417627},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,31]],"date-time":"2009-05-31T00:00:00Z","timestamp":1243728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00280-009-1027-4","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T03:47:38Z","timestamp":1243655258000},"page":"235-241","source":"Crossref","is-referenced-by-count":32,"title":["Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors"],"prefix":"10.1007","volume":"65","author":[{"given":"Apostolia Maria","family":"Tsimberidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Goldsweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,31]]},"reference":[{"issue":"12","key":"1027_CR1","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/13543784.8.12.2121","volume":"8","author":"Y Kloog","year":"1999","unstructured":"Kloog Y, Cox AD, Sinensky M (1999) Concepts in Ras-directed therapy. Expert Opin Investig Drugs 8(12):2121\u20132140 (December)","journal-title":"Expert Opin Investig Drugs"},{"key":"1027_CR2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.bi.62.070193.004223","volume":"62","author":"DR Lowy","year":"1993","unstructured":"Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62:851\u2013891","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"1027_CR3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0962-8924(00)01740-2","volume":"10","author":"JM Shields","year":"2000","unstructured":"Shields JM, Pruitt K, McFall A, Shaub A, Der CJ (2000) Understanding Ras: \u2018it ain\u2019t over \u2018til it\u2019s over\u2019. Trends Cell Biol 10(4):147\u2013154 (April)","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1027_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11\u201322 (January)","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"1027_CR5","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49(17):4682\u20134689 (1 September)","journal-title":"Cancer Res"},{"issue":"8","key":"1027_CR6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jm00008a004","volume":"38","author":"D Marciano","year":"1995","unstructured":"Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y (1995) Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38(8):1267\u20131272 (14 April)","journal-title":"J Med Chem"},{"issue":"3","key":"1027_CR7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","volume":"1452","author":"G Elad","year":"1999","unstructured":"Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y (1999) Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452(3):228\u2013242 (9 December)","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"1027_CR8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s001099900052","volume":"77","author":"B Jansen","year":"1999","unstructured":"Jansen B, Heere-Ress E, Schlagbauer-Wadl H et al (1999) Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med 77(11):792\u2013797 (November)","journal-title":"J Mol Med"},{"issue":"22","key":"1027_CR9","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN et al (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272(22):14459\u201314464 (30 May)","journal-title":"J Biol Chem"},{"issue":"15","key":"1027_CR10","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1074\/jbc.272.15.10232","volume":"272","author":"FL Zhang","year":"1997","unstructured":"Zhang FL, Kirschmeier P, Carr D et al (1997) Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272(15):10232\u201310239 (11 April)","journal-title":"J Biol Chem"},{"issue":"5116","key":"1027_CR11","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1126\/science.8316834","volume":"260","author":"GL James","year":"1993","unstructured":"James GL, Goldstein JL, Brown MS et al (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260(5116):1937\u20131942 (25 June)","journal-title":"Science"},{"issue":"5116","key":"1027_CR12","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1126\/science.8316833","volume":"260","author":"NE Kohl","year":"1993","unstructured":"Kohl NE, Mosser SD, deSolms SJ et al (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260(5116):1934\u20131937 (25 June)","journal-title":"Science"},{"issue":"1","key":"1027_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","volume":"61","author":"R Haklai","year":"2008","unstructured":"Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y (2008) Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61(1):89\u201396 (January)","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1027_CR14","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-06-4287","volume":"67","author":"R Blum","year":"2007","unstructured":"Blum R, Elkon R, Yaari S et al (2007) Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 67(7):3320\u20133328 (1 April)","journal-title":"Cancer Res"},{"issue":"9","key":"1027_CR15","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1535-7163.MCT-06-0193","volume":"5","author":"R Blum","year":"2006","unstructured":"Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y (2006) Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 5(9):2337\u20132347 (September)","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"1027_CR16","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1073\/pnas.96.24.14019","volume":"96","author":"B Jansen","year":"1999","unstructured":"Jansen B, Schlagbauer-Wadl H, Kahr H et al (1999) Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96(24):14019\u201314024 (23 November)","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1027_CR17","first-page":"555","volume":"8","author":"M Gana-Weisz","year":"2002","unstructured":"Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y (2002) The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8(2):555\u2013565 (February)","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1027_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216 (2 February)","journal-title":"J Natl Cancer Inst"},{"key":"1027_CR19","unstructured":"Concordia Pharmaceuticals, Inc., Ft. Lauderdale, FL, Company report"},{"issue":"4","key":"1027_CR20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF03189968","volume":"16","author":"VP Shah","year":"1991","unstructured":"Shah VP, Midha KK, Dighe S et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16(4):249\u2013255 (October\u2013December)","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1027_CR21","first-page":"409","volume-title":"Noncompartmental analysis based on statistical moment theory Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory Pharmacokinetics. Marcel Dekker, New York, pp 409\u2013417"},{"issue":"1","key":"1027_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00130404-200401000-00006","volume":"10","author":"Y Hirokawa","year":"2004","unstructured":"Hirokawa Y, Tikoo A, Huynh J et al (2004) A clue to the therapy of neurofibromatosis type 2: NF2\/merlin is a PAK1 inhibitor. Cancer J 10(1):20\u201326 (January\u2013February)","journal-title":"Cancer J"},{"issue":"2","key":"1027_CR23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1016-8478(23)13217-1","volume":"20","author":"JR Jung","year":"2005","unstructured":"Jung JR, Kim H, Jeun SS, Lee JY, Koh EJ, Ji C (2005) The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway. Mol Cells 20(2):196\u2013200 (31 October)","journal-title":"Mol Cells"},{"issue":"2","key":"1027_CR24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007) Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67(2):520\u2013527 (15 January)","journal-title":"Cancer Res"},{"issue":"1","key":"1027_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.spen.2006.01.007","volume":"13","author":"KH Yohay","year":"2006","unstructured":"Yohay KH (2006) The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol 13(1):21\u201326 (March)","journal-title":"Semin Pediatr Neurol"},{"issue":"5","key":"1027_CR26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ijc.21222","volume":"117","author":"W Yue","year":"2005","unstructured":"Yue W, Wang J, Li Y, Fan P, Santen RJ (2005) Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 117(5):746\u2013754 (10 December)","journal-title":"Int J Cancer"},{"issue":"1","key":"1027_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.cad.0000185184.64980.39","volume":"17","author":"RJ Santen","year":"2006","unstructured":"Santen RJ, Lynch AR, Neal LR, McPherson RA, Yue W (2006) Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Anticancer Drugs 17(1):33\u201340 (January)","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1027_CR28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1523-1755.2005.00425.x","volume":"68","author":"A Khwaja","year":"2005","unstructured":"Khwaja A, Sharpe CC, Noor M, Kloog Y, Hendry BM (2005) The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. Kidney Int 68(2):474\u2013486 (August)","journal-title":"Kidney Int"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1027-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1027-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:35:28Z","timestamp":1710376528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1027-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,31]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["1027"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1027-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,31]]}}}